Filing summary: OmniLit Acquisition Corp. Form 10-K
Entity note: The supplied filing is for OmniLit Acquisition Corp., not Syntec Optics Holdings, Inc. OmniLit was a blank-check company (SPAC) seeking a business combination; it had no operating business or operating revenue during 2022. This is an annual report for the year ended December 31, 2022, not a standalone fourth-quarter report.
Business context and reporting period
OmniLit stated that it intended to focus on advanced manufacturing, particularly optics and photonics, while retaining the ability to pursue other sectors. It had not selected a target or begun substantive discussions with a prospective target by year-end. Management described a target enterprise-value range of approximately $350 million to $750 million.
In December 2022, stockholders approved an extension of the business-combination deadline from February 12, 2023 to November 12, 2023, without requiring an additional trust deposit. The filing was signed January 30, 2023.
Financial results and position
| Metric | 2022 | Prior comparison |
|---|---|---|
| Operating revenue | None | None; 2021 figures cover inception on May 20 through year-end, not a full year |
| Operating costs | $787,639 | $171,167 for the 2021 inception period |
| Interest earned on trust investments | $2,081,055 | $1,679 |
| Net income (loss) | $847,623 | $(169,488) for the 2021 inception period |
| Basic and diluted earnings (loss) per share | $0.05 for Class A and Class B | $(0.01) for each class in the 2021 inception period |
| Trust investments and cash | $14,011,070 | $146,626,679 |
| Cash outside the trust | $117,506 | $494,599 |
| Current assets / current liabilities | $260,696 / $117,070 | $666,507 / $204,095 |
| Total liabilities | $617,070, including a $500,000 deferred underwriting fee | $5,235,345, including a $5,031,250 deferred fee |
The $133,917,056 trust outflow reflects redemption of 13,026,951 public shares at approximately $10.28 per share after the extension vote, leaving 1,348,049 public shares outstanding at December 31, 2022. The deferred underwriting fee was reduced by the underwriters to $500,000 and is payable only if a business combination closes.
The audited cash-flow statement reports $644,474 of net cash used in operating activities in 2022. The MD&A also describes operating cash use as $787,639, which matches operating costs rather than the cash-flow statement total. No debt or long-term lease obligations were reported. The filing provides no operating margin measure because the company had no operating revenue.
Changes, outlook, risks, and unusual items
- The large decline in trust assets was principally due to the 2022 redemptions. Net income was driven by trust interest, not operating activity.
- The auditor issued an unqualified opinion but included a going-concern explanatory paragraph, citing a significant working-capital deficiency, losses, and the need for additional funds. Management said the company expected to complete a transaction before the November 12, 2023 deadline, while acknowledging uncertainty about available working capital. The sponsor committed access to $100,000 of additional working capital if needed.
- If no business combination is completed by the extended deadline, the company must redeem remaining public shares and liquidate, subject to the filing’s terms. Management stated that it expected to have insufficient working capital through the earlier of a transaction or one year from filing.
- Management identified potential financing needs to complete a transaction or address redemptions; sponsor or affiliated working-capital loans were possible but not committed, and up to $1.5 million could be converted into warrants at the lender’s option. The filing says no such loans were outstanding at year-end.
- Risks include no identified target, intense competition for acquisitions, dependence on a single post-combination business, sponsor and management conflicts, and potential third-party claims against trust assets. The company said the sponsor’s ability to satisfy its trust-protection indemnity could not be assured.
- Management cited possible effects from COVID-19 and the Russia-Ukraine conflict, but said specific impacts could not be determined. No specific financial guidance was provided.
- Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the latest quarter. The independent auditor did not attest to internal controls, consistent with the company’s emerging-growth-company status.
Important facts for investors to verify
- Confirm the issuer: this document reports OmniLit Acquisition Corp.’s SPAC financials, not Syntec Optics Holdings, Inc.’s operating results.
- Review the cash-flow statement and MD&A reconciliation for the conflicting descriptions of 2022 operating cash use ($644,474 versus $787,639).
- Check the latest filings for business-combination progress, deadline changes, remaining trust balance, redemptions, and any new financing or loans.
- Assess whether outside-trust cash and the sponsor’s $100,000 commitment are sufficient to fund operations and transaction expenses; note the auditor’s going-concern warning.
- Review the eventual transaction’s dilution, redemption terms, deferred underwriting fee, warrant terms, and related-party arrangements.